Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
about
Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewFLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3.The importance of FLT3 mutational analysis in acute myeloid leukemia.A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia.A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies
P2860
Q28301344-BFEB011A-F1F7-443E-AC36-E2591BC9B32FQ34993145-4623A237-B1C4-42C6-BE63-7429E6FCAF58Q35114397-7A128F15-C1F7-4E0C-AB19-F2FC6625CA26Q35615901-E320360F-D6DF-4926-9AD7-929FBB80CE4BQ35751114-E26E39BB-FE20-43BB-BC96-AE9F3C00F0B9Q35848938-C1728E5A-9535-4901-A29E-508907155272Q35849643-1700495E-0B0E-4995-9B31-B40CCEB0A35BQ36183556-6E237230-51FD-467C-A851-E598EDAE6216Q36591388-2F848D16-1726-4758-A49C-762ABA7B6C4DQ37183513-48D32C9B-3112-4AC8-84B2-C32148249FBFQ37623535-52B9A557-D8EC-493D-A3D1-CCC9A50BF01EQ38721796-A326C7B4-6DE3-49B8-BCC4-D1F44F03F66BQ46608658-B994A9F1-DC98-4369-8E08-01D28BBB1ACBQ48255430-B11E2791-AB60-4C1E-9D2B-19A356BD5AD1Q54645702-8771E83E-0475-476B-9DDA-94CA66B0155EQ59315418-EEFDAD84-74E5-4B8E-8FFF-467B88BCF59D
P2860
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
@en
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
@nl
type
label
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
@en
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
@nl
prefLabel
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
@en
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
@nl
P2093
P2860
P1476
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
@en
P2093
Cheryl L Willman
Derek L Stirewalt
Era Pogosova-Agadjanyan
Jerald P Radich
Kayla M Sheets
Soheil Meshinchi
Steven J Kussick
P2860
P304
P356
10.1111/J.1365-2141.2004.04808.X
P407
P577
2004-02-01T00:00:00Z